Drug Dependence — Clinical Documentation Guide (2026)

🔍 Definition

Drug dependence (substance use disorder) is a chronic, relapsing brain disease characterized by compulsive drug seeking and use despite harmful consequences, driven by neurobiological changes in reward, stress, and inhibitory control circuits. Per the SAMHSA and American Psychiatric Association (APA), substance use disorders exist on a spectrum from mild to severe, formerly captured in DSM-IV as "abuse" and "dependence" — now unified under the DSM-5 framework as a single disorder with severity specifiers. For coding purposes, ICD-10-CM Chapter 5 (F10–F19) retains the use/abuse/dependence hierarchy per FY2026 ICD-10-CM Official Guidelines Section I.C.5.

The ICD-10-CM axis for this chapter organizes disorders by: (1) substance type (F10 alcohol through F19 other/multiple), (2) clinical severity within each substance (use, abuse, dependence, unspecified), and (3) associated complications (intoxication, withdrawal, mood disorder, psychotic disorder, etc.). Accurate code assignment requires the provider to explicitly document the specific substance, the level of use (use vs. abuse vs. dependence), and any active complications or comorbidities arising from the substance use.

🗂️ Alternative Terminology

Providers may use a wide variety of clinical, colloquial, and DSM-5/ICD terms. Coders and CDI specialists must recognize all of the following as potentially codeable diagnoses requiring clarification of severity and substance:

🩺 Signs & Symptoms

Clinical manifestations vary by substance but share common themes of tolerance, withdrawal, and loss of control. The following align with DSM-5 criteria (APA DSM-5) and are organized by domain:

General Substance Use Disorder Criteria (DSM-5 — 2 or more = mild; 4–5 = moderate; 6+ = severe)

• Taking larger amounts or over longer periods than intended
• Persistent desire or unsuccessful efforts to cut down/control use
• Great deal of time spent obtaining, using, or recovering from effects
• Craving or strong urge to use
• Failure to fulfill major role obligations (work, school, home)
• Continued use despite social/interpersonal problems caused by substance
• Important activities given up or reduced due to use
• Recurrent use in physically hazardous situations
• Continued use despite knowledge of persistent physical or psychological problems
• Tolerance: need for markedly increased amounts; diminished effect with same amount
• Withdrawal: characteristic syndrome; substance taken to relieve/avoid withdrawal

Substance-Specific Signs

• Alcohol (F10): Tremors, diaphoresis, tachycardia, hypertension, seizures (delirium tremens), hepatomegaly, peripheral neuropathy, blackouts
• Opioids (F11): Pinpoint pupils, respiratory depression, sedation, nausea/vomiting; withdrawal: rhinorrhea, lacrimation, piloerection, diarrhea, tachycardia, restlessness, COWS score >8
• Cannabis (F12): Conjunctival injection, increased appetite, dry mouth, impaired memory, amotivational syndrome
• Sedatives (F13): Ataxia, slurred speech, cognitive impairment; withdrawal: anxiety, insomnia, tremor, seizures — potentially life-threatening
• Cocaine/Stimulants (F14/F15): Tachycardia, hypertension, dilated pupils, paranoia, nasal septum perforation (cocaine), hyperthermia; crash: fatigue, depression, hypersomnia
• Nicotine/Tobacco (F17): Cravings, irritability, anxiety, difficulty concentrating, increased appetite on cessation; clinically silent long-term toxicity (COPD, CAD, lung cancer)
• Hallucinogens (F16): Perceptual distortions, flashbacks (HPPD), dissociation, autonomic arousal
• Inhalants (F18): Sudden sniffing death, perioral rash, chemical odor, encephalopathy

🧭 Differential Diagnosis

Distinguishing substance use disorders from related and comorbid conditions is critical for accurate ICD-10-CM coding. Many neuropsychiatric symptoms may be substance-induced or represent independent comorbidities — documentation must distinguish between the two per FY2026 Official Guidelines Section I.C.5.

📋 Clinical Indicators for Coders/CDI

The following indicators — when present in the medical record — suggest a codeable substance use disorder, a higher severity level, or a complication requiring additional codes. CDI specialists should review these triggers and query when documentation is absent or ambiguous.

🦴 Anatomy & Pathophysiology

Substance use disorders involve disruption of the brain's mesolimbic dopamine reward pathway — colloquially called the "reward circuit" — involving the ventral tegmental area (VTA), nucleus accumbens, prefrontal cortex, and amygdala. Per NIDA (National Institute on Drug Abuse), all addictive substances trigger dopamine surges 2–10× greater than natural rewards, reinforcing drug-seeking behavior through neuroplastic changes.

Key Neurobiological Mechanisms by Substance Class

• Alcohol (F10): Enhances GABA-A receptor activity (inhibitory) and inhibits NMDA glutamate receptors (excitatory). Chronic use leads to compensatory upregulation of NMDA and downregulation of GABA, causing CNS hyperexcitability on withdrawal — the basis of alcohol withdrawal seizures and delirium tremens (F10.231, F10.232).
• Opioids (F11): Bind mu, kappa, and delta opioid receptors; suppress pain and activate reward via dopamine disinhibition. Chronic use causes receptor downregulation and desensitization → tolerance. Abrupt cessation unmasks noradrenergic hyperactivity (locus coeruleus) → withdrawal syndrome (F11.23).
• Cannabis (F12): THC binds CB1 cannabinoid receptors in prefrontal cortex, hippocampus, and cerebellum, disrupting memory consolidation and executive function. Long-term use associated with amotivational syndrome and cannabis use disorder in ~9% of users per NIDA cannabis research.
• Sedatives/Benzodiazepines (F13): Similar to alcohol — GABA potentiation. Withdrawal shares life-threatening features (seizures, delirium). Cross-tolerance with alcohol. Physiological dependence can develop within 4–6 weeks of daily therapeutic use.
• Cocaine/Stimulants (F14/F15): Block dopamine, norepinephrine, and serotonin reuptake transporters → massive monoamine surge. Methamphetamine also causes direct monoamine release. Chronic use depletes dopamine stores, causing anhedonia and depression in withdrawal ("crash").
• Nicotine (F17): Binds nicotinic acetylcholine receptors (nAChR), particularly α4β2 in VTA → dopamine release. Neuroadaptation to nicotine is rapid; cessation triggers irritability, anxiety, difficulty concentrating, and intense craving (F17.213 withdrawal).
• Hallucinogens (F16): Classic psychedelics (LSD, psilocybin) act as 5-HT2A receptor agonists. Phencyclidine (PCP) is an NMDA receptor antagonist. Dissociative anesthetic at high doses.
• Inhalants (F18): Volatile hydrocarbons enhance GABA and inhibit NMDA activity; direct CNS, cardiac, hepatic, and renal toxicity. Sudden sniffing death via cardiac dysrhythmia.

💊 Medication Impact / Treatment

Pharmacological treatment of substance use disorders is evidence-based and FDA-approved for several substance classes. Medication-Assisted Treatment (MAT) for opioid use disorder represents the gold standard per SAMHSA MAT guidelines and ASAM Clinical Practice Guidelines.

FDA-Approved Pharmacotherapy by Substance

• Opioid Use Disorder (F11.2x):
  • Buprenorphine (Subutex)/Buprenorphine-Naloxone (Suboxone): Partial mu-opioid agonist; first-line MAT. HCPCS J0570–J0575 (buprenorphine formulations), J0592 (buprenorphine-naloxone/Suboxone). Code OUD (F11.2x) + G2086/G2087/G2088 for office-based OUD treatment (Medicare).
  • Methadone (opioid agonist): Full mu-agonist; dispensed at licensed OTPs (opioid treatment programs). HCPCS J3490 (unclassified). Both F11.20 (dependence, uncomplicated) + Z79.891 may apply when methadone serves dual purpose.
  • Naltrexone (Vivitrol): Opioid antagonist; blocks effects. Injectable monthly formulation. HCPCS J2315. Appropriate for sustained remission maintenance.
  • Naloxone (Narcan): Emergency opioid reversal — NOT maintenance treatment; for acute poisoning (T40.xx1A).
• Alcohol Use Disorder (F10.2x):
  • Naltrexone (oral/injectable): Reduces craving. HCPCS J2315 (Vivitrol IM).
  • Acamprosate (Campral): Reduces withdrawal-related dysphoria; restores GABA/glutamate balance. Oral only.
  • Disulfiram (Antabuse): Aversion therapy — causes acetaldehyde accumulation with alcohol ingestion → nausea, flushing, tachycardia.
  • Benzodiazepines (CIWA protocol): Management of acute alcohol withdrawal (F10.23x) — diazepam, lorazepam, chlordiazepoxide.
• Nicotine/Tobacco Use Disorder (F17.2xx):
  • Nicotine Replacement Therapy (NRT): Patches, gum, lozenge, inhaler, nasal spray — reduce withdrawal severity.
  • Varenicline (Chantix/Champix): Partial α4β2 nAChR agonist; most effective single agent per AHRQ Clinical Practice Guideline for Treating Tobacco Use.
  • Bupropion (Zyban): NDRI; reduces craving and withdrawal. Can combine with NRT.
• Stimulant/Cocaine Use Disorder: No FDA-approved pharmacotherapy; contingency management and CBT are mainstay per NIDA treatment principles.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides